| 摘要 |
The invention relates to an antidiabetic pharmaceutical composition in solid form suitable for oral administration to a subject, which comprises a compound of formula (I) or a salt thereof, wherein the solid pharmaceutical composition, after administration to a subject, is capable of providing in the subject an AUC→∞ for the compound (I) of at least, or about, 150-5000 ng∙hr/mL. The composition comprises a compound of formula (I) provided in the form of benzenesulfonate (besylate) salt and constituting about 0.6 to 7.0% of the composition; lactose monohydrate constituting about 25 to about 35% of the composition; crospovidone constituting about 4 to about 5% of the composition; microcrystalline cellulose constituting about 50 to about 60% of the composition; povidone constituting about 1 to about 3% of the composition; optionally; magnesium stearate constituting about 0.25 to about 1.5% of the composition, wherein all percentages are percentages by weight. Provided further are methods of manufacturing the compositions, and methods of treating a PPARγ-mediated condition. |
